MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

<p>Imugene using MaxCyte’s Flow Electroporation® tech</p>
<p>The post <a href="https://forextv.com/top-news/maxcyte-signs-strategic-platform-license-with-imugene-to-advance-their-cancer-immunotherapy-programs/">MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>